Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.
Al Khoury A, Xiao Y, Golovics PA, Kohen R, Afif W, Wild G, Friedman G, Galiatsatos P, Hilzenrat N, Szilagyi A, Wyse J, Cohen A, Bitton A, Bessissow T, Lakatos PL.
Al Khoury A, et al.
Dig Liver Dis. 2021 Aug;53(8):980-986. doi: 10.1016/j.dld.2021.02.006. Epub 2021 Feb 24.
Dig Liver Dis. 2021.
PMID: 33640302